Bimzelx was approved for the treatment of moderate or severe plaque psoriasis. If you have psoriasis under your arms, aka inverse psoriasis, you might wonder if it’s OK to use deodorant or ...

Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal ...

The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...

A doctor may prescribe injectable treatments, such as methotrexate, TNF-alpha inhibitors, or interleukin inhibitors, for moderate to severe psoriasis when other treatments don’t work.

Age at initiation of treatment and the type of biologic therapy prescribed effect the rate of drug survival among patients with psoriasis.

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

holds the crown as the leading segment in revenue generation within the plaque psoriasis market as of 2023. These treatments are gaining rapid traction, embraced increasingly by healthcare ...

The following is a summary of “Global Delphi consensus on treatment goals for generalised pustular psoriasis,” published in the January 2025 issue of Dermatology by Barker et al. Generalized pustular ...

Vanda and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise imsidolimab to ...

AX-158 has achieved clinical validation through its phase 2a trial for the treatment of patients with mild to moderate plaque ...

White matter and other changes around the toenails and fingernails can occur with psoriasis or nail fungus. However, fungal infections are contagious, and psoriasis is not. The causes and ...

Gumokimab is the eighth successfully approved drug developed independently by Akeso (with six already approved for market), and it is also the third non-oncology innovative drug, following ebronucimab ...